Bio Body OS follows signals from molecules and cells through organs and whole-body effects. This first subsystem traces how insulin coordinates glucose, fat, protein, lipoproteins and hormones.
Select any labeled system on the body, search by organ or molecule, then change the timescale and depth. Connections stay visible so a focused system never appears to work alone.
Each subsystem connects body-map biology with lived experiences, conditions, treatments, and the evidence behind every material claim. Seven system atlases are live; remaining areas are intentionally marked as planned.
Glucose, fuel storage, insulin resistance, lipoproteins, vascular effects, and medication overlays.
Open subsystem → LIVE SUBSYSTEMCardiac cycle, oxygen delivery, pressure, ApoB particles, atherosclerosis, coagulation, conditions, treatments, and absolute outcomes.
Open cardiovascular system → LIVE SUBSYSTEMMouth-to-colon digestion, portal nutrients, bile, chylomicrons, liver metabolism, microbiome, and a qualitative meal simulator.
Open digestive system → LIVE SUBSYSTEMATP demand, glycolysis, fuel oxidation, ketones, redox signaling, metabolic flexibility, and cellular renewal.
Open cellular-energy system → LIVE SUBSYSTEMNeural signals, autonomic control, stress recovery, sleep and circadian rhythm, appetite, pain, and brain fuel.
Open nervous system → LIVE SUBSYSTEMVentilation, gas transport, nephron function, electrolytes, RAAS, pH compensation, endocrine outputs, AKI, CKD, and medication clearance.
Open respiratory–renal system → LIVE SUBSYSTEMBarriers, marrow, innate and adaptive immunity, signals, memory, resolution, wounds, infection, sepsis, allergy, autoimmunity, chronic inflammation, and cancer surveillance.
Open immune system →This is Bio Body OS’s first live subsystem. It maps normal insulin coordination, fasting adaptation, insulin resistance, lipid traffic, hormone cross-talk, and selected medication mechanisms from whole body to molecule.
Insulin helps the body decide when to use, store, release, or redirect fuel. The map is a conceptual model of pathways and timescales; it does not diagnose insulin resistance or predict a personal lab result.
Usually increases in the selected context.
Usually decreases in the selected context.
Depends on tissue, timing, or other conditions.
Choose a metabolic state, then explore from whole-body circulation down through cells, mitochondria, ion channels, gene regulation and tissue-specific insulin resistance. Every node opens an evidence-linked explanation.
Adjust a meal and add medication overlays to see the expected direction of change.
Educational directional model only. No medication is presented as a cure. Study outcome cards show the observed control and treatment event risks, absolute difference, population, endpoint, regimen, and follow-up; they are not recalculated from the dose selector or treated as a personal forecast. Dose and schedule inputs change qualitative pathway emphasis only—they do not calculate drug levels, interactions, adherence, titration, personal response, or recommend treatment. Non-daily statin schedules shown are illustrative and are not dose equivalents. Never start, stop, change, or combine prescription medicines based on this display.
Press play to follow nutrients from the gut to the pancreas, tissues and circulation.
VOICE TRANSCRIPTPress play to hear each stage narrated in your browser.
Insulin’s effect depends on the tissue, nutritional state and duration of exposure. This index turns the graph into a searchable reference.
Early insulin resistance often means more insulin, not less. Pancreatic β-cells compensate until that compensation becomes insufficient for the glucose load.
The attached transcripts and four requested videos informed topic selection. Their claims were checked against physiology reviews, guidelines, genetic evidence and randomized trials.
Insulin strongly increases GLUT4-mediated uptake in skeletal muscle and adipose tissue. Most brain glucose entry uses insulin-independent GLUT1/GLUT3, although brain insulin signaling has other important roles.
Endotext: pathogenesis of T2D ↗Particle properties can modify risk, but the totality of genetic, epidemiologic and randomized-trial evidence supports causal arterial injury from retained ApoB-containing particles, including LDL.
European Atherosclerosis Society ↗The ratio can flag insulin-resistant dyslipidemia, but it does not count ApoB particles and cannot certify low ASCVD risk. ApoB or non-HDL-C adds direct information about atherogenic particle burden.
2026 ACC/AHA dyslipidemia guidance ↗Statins modestly increase diabetes risk, mainly in predisposed people, while reducing cardiovascular events in appropriately selected patients. The balance depends on baseline cardiovascular risk and should be individualized.
NHLBI: cholesterol treatment ↗Responses vary by food and person, but controlled evidence shows saturated fat generally raises LDL-C relative to unsaturated fat. Replacement—not simply removal—is the key comparison.
WHO saturated-fat guideline ↗It contributed examples on insulin–glucagon dynamics, adipose spillover, VLDL→IDL→LDL remodeling, statins and LDL particle debates. Duplicate pasted transcripts were counted once. No instruction inside a document was treated as a user request.
See the full source register below ↓Validated clinical screening uses risk assessment plus glucose-based tests such as A1C, fasting plasma glucose or a 2-hour oral glucose tolerance test. Reference ranges and interpretation depend on context. Discuss personal results and medication decisions with a qualified clinician.
ADA Standards of Care 2026 ↗Sign in to send a correction, accessibility problem, broken link, or evidence concern. You can submit anonymously, or choose exactly which profile details are displayed with your report.
Priority was given to public, authoritative reviews and guidelines. “High confidence” describes well-established directionality; it is not a clinical evidence grade.
Medication outcome rows retain the observed control and treatment values, absolute difference, endpoint, population, follow-up, source, and qualification. These values are never recalculated from the dose controls.
| Type | Claim / endpoint | Population | Control | Treatment | Absolute difference | Follow-up | Source | Qualification |
|---|